Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach |
Sood, Damini
(Drug Discovery & Development Laboratory, Department of Chemistry, University of Delhi)
Kumar, Neeraj (Drug Discovery & Development Laboratory, Department of Chemistry, University of Delhi) Singh, Aarushi (Drug Discovery & Development Laboratory, Department of Chemistry, University of Delhi) Sakharkar, Meena Kishore (College of Pharmacy and Nutrition, University of Saskatchewan) Tomar, Vartika (Drug Discovery & Development Laboratory, Department of Chemistry, University of Delhi) Chandra, Ramesh (Drug Discovery & Development Laboratory, Department of Chemistry, University of Delhi) |
1 | Aldred KJ, McPherson SA, Turnbough CL Jr, Kerns RJ, Osheroff N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res 2013;41:4628-4639. DOI |
2 | Crumplin GC, Kenwright M, Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother 1984;13 Suppl B:9-23. |
3 | Nicolle LE. Management of acute uncomplicated pyelonephritis. In: Urinary Tract Infections (Bergan T, ed.). Basel: Karger, 1997. pp. 8-13. |
4 | Owens RC Jr, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am 2000;84:1447-1469. DOI |
5 | Appelbaum PC. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995;49 Suppl 2:76-80. DOI |
6 | King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am Fam Physician 2000;61:2741-2748. |
7 | Sharma PC, Jain A, Jain S, Pahwa R, Yar MS. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J Enzyme Inhib Med Chem 2010;25:577-589. DOI |
8 | Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989;111:1041-1043. DOI |
9 | World Health Organization. WHO Model List of Essential Medicines. 19th list. Geneva: World Health Organization, 2015. |
10 | Wadworth AN, Goa KL. Lomefloxacin. A review of its anti- bacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1991;42:1018-1060. DOI |
11 | Barza M. Use of quinolones for treatment of ear and eye infections. Eur J Clin Microbiol Infect Dis 1991;10:296-303. DOI |
12 | Cox CE. Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Am J Med 1989;87:61S-68S. DOI |
13 | DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1997;92:1962-1975. |
14 | Gadade DD, Sarda K, Shahi SR. Investigation and optimization of the effect of polymers on drug release of nor- floxacin from floating tablets. Polim Med 2016;46:117-127. |
15 | Nagaraja V, Godbole AA, Henderson SR, Maxwell A. DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov Today 2017;22:510-518. DOI |
16 | Alves MJ, Froufe HJ, Costa AF, Santos AF, Oliveira LG, Osorio SR, et al. Docking studies in target proteins involved in antibacterial action mechanisms: extending the knowledge on standard antibiotics to antimicrobial mushroom compounds. Molecules 2014;19:1672-1684. DOI |
17 | Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph 1990;8:52-56, 29. DOI |
18 | Kumar N, Tomar R, Pandey A, Tomar V, Singh VK, Chandra R. Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer. Artif Cells Nanomed Biotechnol 2018;46:1288-1299. DOI |
19 | Singh V, Kumar N, Chandra R. Structural insights of induced pluripotent stem cell regulatory factors Oct4 and its interaction with Sox2 and Fgf4 gene. Adv Biotechnol Biochem 2017; (5):J119. |
20 | Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010;466:935-940. DOI |
21 | Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, et al. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins 2003;50:437-450. DOI |
22 | Luthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature 1992;356:83-85. DOI |
23 | Ghoorah AW, Devignes MD, Smaïl-Tabbone M, Ritchie DW. Protein docking using case-based reasoning. Proteins 2013;81: 2150-2158. DOI |
24 | Goddard TD, Huang CC, Ferrin TE. Visualizing density maps with UCSF Chimera. J Struct Biol 2007;157:281-287. DOI |
25 | Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and per- meability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26. DOI |
26 | Lagorce D, Maupetit J, Baell J, Sperandio O, Tufféry P, Miteva MA, et al. The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections. Bioinformatics 2011;27:2018-2020. DOI |
27 | Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7: 42717. DOI |
28 | ACD-I Lab. Toronto: Advanced Chemistry Development, Inc., 2015. Accessed 2018 May 2. Available from: http://www.acdlabs.com. |